RSS Feeds
Rituximab for Patients with Idiopathic Thrombocytopenic Purpura
- Francisco Javier Peñalver, MD; and
- Jose Rafael Cabrera, MD, PhD
- From Fundación Hospital Alcorcón, 28922, Alcorcón, Madrid, Spain, and Hospital Universitario Puerta de Hierro, 28035 Madrid, Spain.
TO THE EDITOR:
We read Arnold and colleagues' systematic review (1) on the use of rituximab for idiopathic thrombocytopenic purpura (ITP) with great interest. The authors mentioned a study by our group (2) but had excluded it from their meta-analysis, claiming that our study “did not report original data.” We cannot agree with this statement, for our report certainly compiles original data, which were reported previously in abstract form only (3). Our study fulfills sufficient criteria for inclusion in the meta-analysis. Our retrospective, multicenter study assessed the therapeutic efficacy and toxicity of …
